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INTRODUCTION
On the last day of 2019, China alerted the WHO of several 
cases of unusual pneumonia in Wuhan by an unknown virus. 
More than 40 infections were noted in workers from the city’s 
Huanan Seafood Wholesale Market, which was shut down on 
the first day of 2020. The first death (heart failure as cause) 
occurred officially on 9 January 2020. Within 2 weeks, similar 
cases were reported from Thailand and several other coun-
tries. A month after the first alert, on 30 January 2020, the 
WHO declared the coronavirus a global emergency.(1) Since 
then, more than 6 million people have been known to be 
infected, with more than 360 000 reported deaths (at time of 
writing, 28 May 2020), and in South Africa more than 26 000 
positive cases have been reported,(2) with the first death in 
South Africa possibly due to possible pulmonary embolism. The 
coronavirus disease of 2019 (COVID-19) is caused by the 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2). Although based on scarce direct evidence, but mostly 
observations/experiences of clinicians treating these patients 
(clinical trials are only being done at time of writing), the 
following observations have been made:
Initially patients may experience the clinical picture of a viremia 
with mild constitutional symptoms of fever, fatigue, headache, 
cough, myalgia, occasionally with gastro-intestinal symptoms 
such as diarrhoea, and some with neurological symptoms (most 
commonly anosmia). In this phase of the disease, laboratory 
abnormalities may already be present, with markers indicating 
increased risk of severe disease and potential for progression to 
mechanical ventilation or ICU admission.(3,4)
These include:
 ■ Lymphopenia (and neutrophil:lymphocyte ratio)
 ■ Increased D-dimer values (>0.5mg/L or >age-adjusted 
value)
 ■ Mildly prolonged prothrombin time
 ■ High fibrinogen degradation products (FDP) values
 ■ Increased LDH levels
A proportion of patients with clinical markers predictive of 
more severe disease such as older age, male gender, comor-
bidities such as hypertension and diabetes, cancer or high BMI, 
may develop pulmonary symptoms such as dyspnea and mild 





COVID-19 is associated with a hypercoagulable state 
that may present as pulmonary thrombosis, pulmonary 
embolism, and venous and arterial thrombosis.
Suggested pathogenesis include direct infection of the 
endothelial cell with subsequent endothelial cell dys-
function, leading to increased procoagulant activity, 
decreased anticoagulant activity and decreased fi bri-
nolysis. The severe immune infl ammatory response in 
the lungs with cytokine release also plays a critical role 
(immunothrombosis). Hypoxia has a local and systemic 
effect on coagulation. Various markers of this state have 
been described, and especially the D-dimer level (and 
rapid changes in the D-dimer level) as a reliable prog-
nostic marker. It is also used as indicator for initiation of 
anticoagulation by some experts. Due to the pleotrophic 
effects of heparin, it is the anticoagulant of choice for 
these patients (most often low molecular weight hep-
arin, due to decreased risk of heparin induced throm-
bocytopenia, ease of use). No clinical trial data is 
available at the time of writing (28 May 2020), and 
suggested guidelines of experts in different countries 
are discussed.  SAHeart 2020;17:266-274
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present, with low procalcitonin.(5) D-dimer levels are increased 
and high acute phase reactant levels such as ferritin and 
interleukin-6 (IL-6) are noted. 
An even smaller proportion of patients may progress to the 
third hyperinflammation or cytokine storm, with very high IL-6 
levels, very high ferritin levels and very high D-dimer (even 
>3mg/L or 6 x upper limit of normal) levels. This leads to organ 
dysfunction including the acute respiratory distress syndrome, 
hypotension, cardiac failure, and renal dysfunction. In the 
terminal stages of the disease, criteria compatible with dissem-
inated intravascular clotting (DIC) may be present – such as 
thrombocytopenia and low fibrinogen level.(6)
A hypercoagulable state is present during the course of the 
disease, and coagulopathy is associated with high mortality.(7) 
Initially, in China, a few reports of venous thrombosis were 
described,(8) but with the spread to Europe, various reports of 
venous(9) as well as arterial thrombosis(10) have been reported. 
An incidence of 31% of VTE has been described in the sick 
ICU COVID-19 patients, despite standard thromboprophy-
laxis.(9) Arterial thrombosis may be due to the systemic inflam-
matory response and vascular inflammation associated with 
vascular plaques. Formation of microvascular thrombi in the 
pulmonary capillaries has been suggested to be part of the 
pathogenesis of the disease. This pulmonary specif ic vascu-
lopathy has been termed pulmonary intravascular coagu-
lopathy (PIC).(11) Anticoagulant therapy is associated with 
decreased mortality in severe COVID cases.(12) Recent publica-
tions describing autopsy findings have confirmed the presence 
of thrombosis in small and mid-sized pulmonary arteries in all 
the patients examined, with pulmonary infarction in more than 
70% of patients.(13) In another recent paper (prospective study 
on the first 12 deaths in a German academic centre), 58% of 
patients at autopsy showed venous thrombo-embolism, in 
whom VTE that had not been suspected prior to death, with PE 
as the direct cause of death in 33% of patients.(14) 
SEVERAL QUESTIONS ARISE FROM THESE 
OBSERVATIONS:
What is the pathogenesis of this hypercoagulable state, 
and is this different from other infl ammatory states?
Four different processes (which are interactive and inter-
dependent) play a role in thrombosis and haemostasis (with 
some of the major role players) (Figure 1). These consist of:
Procoagulant activity
Coagulation factors (CF) circulate in an inactive form, except 
for a small percentage of active Factor VII (FVIIa). Contact with 
FIII [tissue factor (TF)], which is present in tissue as well as 
monocytes, activates the clotting cascade leading to the 
formation of fibrin strands. Thrombin (FIIa) plays the part of 
conductor of this system. FXIIa, which is activated by surface 
contact, including platelets, activates the pro-inflammatory 
kallikrein-kininogen pathway.
Platelet surfaces have receptors for subendothelial structures, 
and when activated, release content such as von Willebrand 
factor (vWF), Factor V, Factor VIII, PAI-1, chemokines, 
FIGURE 1: Four processes of haemostasis.
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fibrinogen, calcium, ATP and ADP. Platelets thus have a 
microbicidal and chemotactic role, supply the phospholipid 
microparticles that are needed for the coagulation pathway, 
and supply clotting factors and activate other platelets.
Neutrophils are known to produce neutrophil extracellular 
traps (NETs), which are fibrous nets with antimicrobial pro-
perties capable of killing bacteria and fungi, and which are also 
released in viral infections. 
Von Willebrand factor (vWF) is a multimer adhesive glyco-
protein present beneath the endothelial cells (to which blood 
platelets can bind). Large multimers of vWF are released by 
endothelial cells under conditions of sheer stress conditions, 
but are quickly cleaved by a metalloproteinase (ADAMTS-13).
Anticoagulant activity
Endothelial cells (EC) (see Figure 2) form a smooth barrier 
between blood and subendothelial structures, control vaso-
motor tone by release of prostacyclin and nitrous oxide, and 
when activated release and express adhesion molecules on the 
inner surface that control cellular traffic (inflammatory cell and 
platelet adhesion and vascular permeability). ECs also play an 
important part in the fibrinolytic pathway by manufacturing 
tissue plasminogen activator (tPA) and plasminogen activator 
inhibitor (PAI-1). EC have a role in activating circulating anti-
coagulants such as protein C, and even have a role in anti-
fibrinolytic activity by activating thrombin activatable fibrinolysis 
inhibitor (TAFI).
Circulating anticoagulants include antithrombin, which inhibits 
thrombin, FIXa, FXa, FXIa and FXIIIa, protein S and protein C 
which inhibit FVa and FVIIIa, and tissue factor pathway inhibitor 
which inhibits FXa.
Fibrinolytic activity
Tissue plasminogen activator (tPA) is a protease that is secreted 
by ECs (stimuli for this includes venous occlusion, thrombin 
(FIIa) and strenuous exercise), which converts plasminogen to 
plasmin. Plasmin hydrolyses fibrinogen and fibrin, with resultant 
D-dimer peptides.
Anti-fibrinolytic activity
Plasminogen activator inhibitor (PAI-1) is secreted by ECs, and 
it inhibits tPA. Thrombin activatable fibrinolysis inhibitor (TAFI) 
FIGURE 2: Endothelial cell role in haemostasis and thrombosis, depending on activation status.
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removes the lysine binding sites of fibrin for plasminogen and 
tPA, thus downregulating fibrinolytic activity.
Of note is the important role of the endothelial cell in all 4 
processes (Figure 2).
Two further concepts are also important: 
There is a strong link between inflammation and thrombosis: 
Cytokine orchestration of both thrombus generation [Inter-
leukin 6 (IL-6), IFN-Υ, IL-17, IL-9 and TGF-β], as well as throm-
bus resolution (IL-10, TNF-α and IL-8) have been reviewed 
recently.(15) This inflammatory response includes activation of 
neutrophils (and thus NET formation), monocytes (with TF 
expression), platelets (with aggregation) and endothelial cells 
(with release of large von Willebrand factor multimers which 
overwhelm the metalloprotease ADAMTS-13).(16)
The effect of hypoxia (local and systemic) on coagulation: 
Hypoxia-inducible transcription factors (HIFs) control the vas-
cular response, with increased expression of tissue factor 
expression and PAI-1, as well as decreased TFPI and protein S 
expression, thus tipping the scale towards a hypercoagulable 
state. Simultaneously, hypoxia also increases the inflammatory 
response and activates platelets.(17)
Suggested pathogenesis of hypercoagulability in 
COVID-19 (Figure 3):
The SARS-CoV-2 virus infects the host by attaching the surface 
spike glycoproteins to the angiotensin-converting enzyme 2 
receptor (ACE-2 receptor) on host cells. The ACE-2 receptors 
are present in many organs, such as lung alveolar cells, heart, 
intestine and kidney podocytes and tubule epithelial cells, but 
also on endothelial cells and pericytes in the vicinity of the 
endothelial cell and lymphocytes. The inhaled virus initially 
attaches to the alveolar cells in the lungs and leads to pneu-
monia with an intense inflammatory response, precipitating an 
exudate of fibrinogen into the alveoli, with fibrin and hyaline 
membrane formation (seen in SARS as well as COVID-19). The 
inflammation in the alveolar cells triggers endothelial dysfunc-
tion, which leads to vasoconstriction and a procoagulant state 
in the vessel, with impaired microcirculation and organ 
ischaemia, recently termed Corona-19-associated hemostasis 
abnormality (CAHA).(18) Evidence has been found of direct viral 
infection of the endothelial cell, causing diffuse inflammation of 
the cells (“endothelialitis”).(19) Due to the sepsis and the inflam-
matory response, monocytes are activated and their TF 
expression activate the coagulation cascade. Platelets are also 
activated with resultant release of content and microparticles. 
Neutrophils are attracted to the area with NET formation 
(NETosis). These NETs activate the coagulation cascade (elec-
trostatic interactions between NET histones and platelet phos-
pholipids activate the “alternate pathway” via the kallikrein-kinin 
system).(20) Monocytes (macrophages) in the area are induced 
to form IL1β (which induces IL-6 production), and when over-
whelmed by the ensuing cytokine storm, this loop leads to an 
uncontrolled progressive inflammatory process.(20) In addition, 
large vWF multimers are released from the endothelial cell. All 
these procoagulant factors leads to a local hypercoagulable 
state with clot formation. Whether a different mechanism is 
involved in COVID-19 infections relative to other causes of 
severe sepsis, is uncertain, but the coexistent hypoxia (see 
above), may play an important role in determining its severity.(16) 
The ACE2 receptor is part of the renin-angiotensin-aldos-
terone system (RAAS). After infection with COVID-19, ACE2 
is downregulated, with an increase in angiotensin II (Ang II) 
levels. This leads to an increase in PAI-1, with inhibition of 
fibrinolysis. Even though the kinin-bradikinin pathway is acti-
vated with an associated increase in tPA, the scale is tipped 
towards hypercoagulability with increased PAI-1 and decreased 
fibrinolysis.(21) In one study,(7) 71% of patients that died of 
COVID-19, fulfilled the criteria for disseminated intravascular 
coagulation (DIC). This occurred at a late stage of the disease 
with associated thrombocytopenia, hypofibrinogenemia, pro-
longed PT, increased D-dimer value, and high SOFA (sequential 
organ failure assessment) score. The important entity of sepsis-
associated coagulopathy (SIC) has been defined by the DIC 
standardisation subcommittee in 2019,(22) and is characterised 
by suppression of fibrinolysis, induced by endothelial dysfunc-
tion (as described above). The importance of this distinction is 
that anticoagulant therapy may improve outcomes in this 
early group of patients that eventually develop overt DIC, as 
SIC procedes DIC (see Figure 3). The presence of anti-
phospholipid antibodies in patients with COVID-19 has also 
been demonstrated, and even could be associated with 
catastrophic antiphospholipid syndrome (APLS).(23)
In view of the increased D-dimer, f ibrinogen, ferritin and 
anaemia (schistocytes are not really noted on blood smears 
though) in association with renal dysfunction, fever and clear 
endothelial cell dysfunction, the pathogenesis of COVID-19 
injury has also been suggested to be due to a secondary 
thrombotic micro-angiopathy (TMA).(24) COVID-19 causes 
alterations in complement regulatory proteins with activation of 
the complement system, and at the same time infects pericytes 
and endothelial cells, leading to endothelial cell dysfunction.
Why is the hypercoagulable state so important 
in COVID-19?
The hypercoagulability, especially when localised to the lungs as 
part of the innate defense mechanism directed against the 
virus, may be an important part to the pathogenesis of the 
clinical picture, as such early anticoagulation has the potential to 
mediate the inflammatory process. It is important to distinguish 
pulmonary thrombosis due to the localised hypercoagulability 
from pulmonary embolism that may be seen in other ICU 
patients. In fact, ultrasound of the legs is often normal, and 
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only by recognition that the hypoxia may not only be due to 
the pneumonia, can the diagnosis of pulmonary thrombosis be 
made.(14) Both intra-pulmonary thrombosis and classical pul-
monary embolism may occur, as once immobilised and mecha-
nically ventilated, all of Virchow’s triad are present: stasis, 
endothelial damage and systemic hypercoagulability. Treatment 
may, however, differ between intra-pulmonary thrombosis and 
pulmonary embolism. With pulmonary embolism, anticoagulant 
therapy is indicated, but with the important role of platelets 
in pulmonary thrombosis, antiplatelet therapy may be of value, 
as well as nebulised antithrombotic therapies in pulmonary 
thrombosis.(18) 
How do we manage this hypercoagulable state?
As no clinical trial data are currently available, there is uncertainty 
as to the timing and dosing of prophylactic anticoagulation. 
Some suggest using D-dimer values and weight-adjusted dosing, 
whereas others suggest different dosages at different stages of 
the disease, but also taking D-dimer values into consideration. 
There are only interim guidelines at the time of writing, but it 
must be emphasised that prior to therapy, bleeding risk should 
first be evaluated.
Timing and dose of anticoagulation (see Figure 4)
Patients in the viremic phase, and in quarantine at home, should 
receive no anticoagulation but are advised to stay active as 
suggested by interim ISTH guidelines.(25) If these patients have 
an underlying hypercoagulable state such as congenital throm-
bophilia, previous VTE, underlying malignancy, or any additional 
risk factor, standard prophylactic anticoagulation is recom-
mended in countries such as United Kingdom, Spain and France. 
In France, Spain and Italy, it is recommended that obese 
patients with additional risk factors receive intermediate doses 
of VTE prophylaxis. D-dimer, CRP and ferritin values may help 
in the decision. A D-dimer value of more than 0.5mg/L (or 
above age-related value cut-off) indicates an increased throm-
botic risk, and an increased CRP and ferritin may indicate 
progression of the disease. Pregnant patients are already 
FIGURE 4: Suggested VTE prophylaxis in COVID-19: No clinical trial data available, based on European experiences and 
country guidelines. 
Anti-FXa measurements are not always readily available, thus clinical factors, D-dimer values and stage of disease are used in decision-
making. If antiFXa is available (South Africa), a more precise safe level appropriate for the patient may be achieved (see text). Bleeding risk 
should always be evaluated prior to initiating anticoagulant therapy. Renal function must be taken into account with use of LMWH. Platelet 
count should regularly be done (adjustment made depending on degree as well as etiology of thrombocytopenia) and the cause of 
thrombocytopenia investigated. 
* Obese patients need higher doses to achieve adequate anticoagulation.(37) Anti-FX activity measurement suggested for prophylaxis as well 
as therapy (when adjusting dosages, in obese and underweight patients and in all ICU patients), Visco-elastography (TEG) measurement 
(with and without heparinase) may be used as a guide to whole blood coagulation status.
COVID-19 positive
Ambulant patient Ward patient
Stay active
Intermediate dose VTE prophylaxis Intermediate dose VTE prophylaxis Therapeutic VTE dose prophylaxis
Standard dose VTE prophylaxis
But with BMI >30*/increased D-dimer or 
additional risk factors, e.g. previous VTE
Obese with additional risk factors
But with BMI >30* or with additional risk 
factors or increased D-dimer >1mg/L
But with BMI >30* or with additional risk 








hypercoagulable and should also receive VTE prophylaxis (they 
should be put on the ISTH registry if possible: https://redcap.
isth.org/surveys/?s=4JPX9W98RH).
Patients admitted to hospital should receive prophylactic 
thromboprophylaxis, irrespective of other additional risk 
factors present. If additional risk factors are known, such as 
obesity, previous VTE, and underlying malignancy, inter-
mediate dose prophylactic anticoagulation is suggested – as 
is the practice in France, Spain, and Italy. 
Patients in the ICU: all patients should receive prophylaxis. 
Some countries still give these patients standard prophylaxis 
(UK, Italy) combined with mechanical prophylaxis (intermittent 
pneumatic compression), but obese patients or patients with 
additional risk factors are given intermediate prophylactic 
doses. France and Spain consider administering therapeutic 
anticoagulation in patients with very high D-dimer values (>6x 
normal value / >3mg/L)
Although the interim ISTH guidelines advise normal prophy-
lactic dosages of heparin (once daily LMWH or twice daily 
UFH), due to the markedly hypercoagulable present in 
COVID-19 patients, some physicians (see countries above) use 
intermediate or even full dose (therapeutic) anticoagulation 
dosages.(22) Anti-Factor X activity (anti-FXa) is not routinely 
measured for prophylactic anticoagulation therapy and no 
validated target values are available from clinical trials, but our 
own experience has indicated that higher doses of LMWH 
are necessary due to high fibrinogen and high FVIII levels. 
Antithrombin levels are mostly not very low. Adequate dose 
titration to achieve antiFXa levels of 0.2 - 0.5IU/ml 3 hours after 
injection may thus be suggested for standard prophylaxis. Inter-
mediate dosing will result in antiFXa levels of 0.4 - 0.8IU/mL, 
and to achieve full treatment anticoagulation, the target value 
of 0.6 - 1.2IU/mL is aimed for. Anti-FXa measurement is sug-
gested for all patients when adjusting dosages due to weight, 
renal dysfunction and increased bleeding risk. Weight based 
adjustments should be made and effect measured at both ends 
of the scale, i.e. less than 40kg and greater than 100kg. Renal 
function must also be monitored in patients receiving LMWH 
and adjustments must also be made for thrombocytopenia.
In the ICU, especially if inotropic support is required, higher 
LMWH doses are needed to achieve expected antiFXa levels 
due to decreased subcutaneous absorption and augmented 
renal clearance. If UFH are used, better control is achieved by 
doing anti-FXa levels specific for UFH, than using the activated 
partial thromboplastin time (aPTT) – especially in the ECMO 
patient. 
Once diagnosed with VTE, initial treatment with LMWH/UFH 
in hospital with therapeutic anti-FXa levels, and discharge on 
either LMWH or DOAC.
Type of anticoagulant
Heparin is known to have anti-inflammatory effects, not only 
because it decreases thrombin (FIIa), but because it binds to 
inflammatory cytokines, inhibits neutrophil chemotaxis, seques-
trates acute phase proteins and neutralizes complement factor 
5a.(26) Heparin also has a potential antiviral effect by inter-
acting with the spike proteins on the COVID-19 virus.(27) For 
all these reasons heparin is used as an anticoagulant rather 
than novel oral anticoagulants. Low molecular weight heparin 
(LMWH) is most often used as there is a much lower risk of 
heparin-induced thrombocytopenia with thrombosis syndrome 
(HITTS), unless renal dysfunction is present or there is an 
expected need for temporary discontinuation related to pro-
cedures, where unfractionated heparin may be used. Once 
discharged or stable the new oral anticoagulants or LMWH 
may be used, reducing the risk of hospital/clinic visits for INR 
control.
How long should patients receive anticoagulation?
Extended prophylaxis for medical patients comes with a risk of 
bleeding, but in those with elevated VTE risk, up to 45 days 
may be considered.(25) An increase in D-dimer value (>2x 
normal) has been suggested as a marker for thrombotic risk 
and an indication for extended VTE prophylaxis in medical 
patients,(28) and may aid in decision-making on when discon-
tinuation of prophylaxis can occur.
Patients that developed VTE during their hospital stay should 
be treated for the normal period, and D-dimer with patient’s 
history and clinical picture may guide the decision on discon-
tinuing anticoagulation.
Which laboratory tests are recommended in monitoring 
COVID-19 patients?
Depending on resources available, different tests may be per-
formed and due to the rapid emerging information, these sug-
gestions may change:
 ■ Patients at risk for developing severe disease: D-dimer, 
prothrombin time (PT), FBC [platelet count, lymphocyte 
and neutrophil counts (neutrophil/lymphocyte ratio)], 
ferritin, CRP, LDH and IL-6 (IL-6/lymphocyte ratio).(29)
 ■ Hospitalised patients: as above, as well as activated partial 
thromboplastin time (aPTT), fibrinogen, U&E and creatinine, 
liver enzymes, cardiac markers, PCT, and anti-Factor X 
activity measurement of LMWH/UFH levels (both in pro-
phylactic and therapeutic dosages).
 ■ Patients in ICU: as above. In addition, we find visco-
elastography testing on whole blood helpful, particularly 
thrombo-elastogram (TEG), especially with and without 
heparinse. Many patients may have prolonged PT values 

















bility – despite prolonged PT values. A TEG performed 
with heparinase also provides additional information on 
other factors involved, such as platelet function (α-angle, 
maximal amplitude), f ibrinogen level (α-angle, maximal 
amplitude), and presence of fibrinolysis (% lysis). TEG may 
be helpful to distinguish DIC from the severe hyper-
inflammatory coagulation abnormality of COVID-19,(30) 
and may help in the decision as to whether to use 
anticoagulation in this “SIC/DIC” state (see above). A 
decrease in platelet count should always be investigated, 
as patients do not commonly develop severe thrombo-
cytopenia. Heparin-induced thrombocytopenia with throm-
bosis syndrome (HITTS), drug reactions, DIC and immune 
thrombocytopenia, are just some of the considerations.(31)
The minimum suggested tests(32) recommend: 
 ■ a complete or full blood count;
 ■ baseline routine coagulation tests (prothrombin time (PT) 
and activated partial thromboplastin time (aPTT));
 ■ fibrinogen; and
 ■ D-dimer (or other associated tests such as fibrin/fibrinogen 
degradation products and fibrin monomers as locally 
available or supported). 
A series of biochemistry and other tests are also suggested, 
including markers for inflammation, electrolyte disturbance, 
liver dysfunction, and renal and cardiac damage. If anti-FXa 
levels are not available, a suggested prophylactic dosage calcu-
lation may be made taking the D-dimer value, stage of the 
disease, and patient’s weight into consideration(33) (Figure 4).
How do we diagnose VTE in COVID-19 patients? 
Computed tomography pulmonary angiography (CTPA) is 
often not possible as patients may be in isolation or very ill and 
D-dimer values are very high in all patients. A high index of 
suspicion for thrombosis is necessary in all COVID-19 patients 
at all stages of the disease, as the diagnosis may be challenging, 
especially in the sick ICU patient with pulmonary thrombosis. 
Worsening right ventricular function may be assessed with 
echocardiography, and disproportionate hypoxemia, unex-
plained right ventricular dysfunction or leg swelling or pain 
should arouse suspicion of VTE (pulmonary thrombosis or 
embolism).(34) 
SUMMARY
SARS-CoV-2 infection leads to a hypercoagulable state: 
 ■ directly due to direct infection of the endothelial cells, and 
 ■ indirectly due to the severe inflammatory response and 
hypoxia that result from the infection. These lead to the 
activation of the coagulation cascade, platelet activation, 
NETosis, endothelial dysfunction and decreased fibri-
nolysis, with SIC. This process may be localised to the lung 
(pulmonary intravascular coagulopathy), but may also be 
systemic (especially with stasis, intravenous lines in the 
ICU) – leading to all 3 VTE risk factors of Virchow’s triad 
present.
 ■ Markers that predict an increased risk of severe disease 
include clinical risk factors such as older age, male gender, 
comorbidities such as hypertension and diabetes, cancer, 
obesity, and laboratory markers such as lymphopenia 
(increased neutrophil: lymphocyte ratio), increased D-dimer 
values, mildly prolonged PT, high FDP values, increased 
LDH levels, increased IL-6 and increased IL-6: lymphocyte 
ratio. Many of the clinical factors are associated with 
underlying endothelial dysfunction in COVID-19 negative 
patients, as well as with VTE risk.
 ■ Pulmonary thrombosis and pulmonary embolism and 
arterial thrombosis are seen in these patients, especially 
during admission, but also during pre-admission and post-
discharge, and a high index of suspicion is critical.
 ■ There is international variability in preventative measures, 
depending on access to resources, but as more and 
more histological (post-mortem) examinations are being 
reported, the severity of the hypercoagulable state of 
COVID-19 is being highlighted,(35) with reports of venous as 
well as arterial thrombotic events, despite “standard” 
anticoagulation prophylaxis.(36)
 ■ Heparin is known to have anti-inflammatory and anti-viral 
effects, as well as its anticoagulant effect, and also to be 
protective of the endothelial cell. Studies have shown that 
prophylactic heparin may decrease mortality in COVID-19, 
and as such, it is the anticoagulant of choice. Measuring anti-
FXa activity levels is suggested for both prophylactic and 
therapeutic management, for both LMWH and UFH. 
Higher doses of LMWH and aiming for at least interme-
diate prophylactic anti-FXa levels may prove vital in 
COVID-19 in patients with additional risk factors or very 
high D-dimer values. Prophylaxis with LMWH aiming at 
therapeutic anti-Fa levels should be considered in the 
severely hypercoagulable patient with D-dimer values of 
>3g/L in the absence of bleeding risk. Renal function and 
platelet count must always be taken into account when 
prescribing anticoagulation.
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